Literature DB >> 10992553

Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast.

A P Sampson1, S Siddiqui, D Buchanan, P H Howarth, S T Holgate, J W Holloway, I Sayers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10992553      PMCID： PMC1765955          DOI： 10.1136/thorax.55.suppl_2.s28

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  15 in total

Review 1.  Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma.

Authors:  M Sanak; A P Sampson
Journal:  Clin Exp Allergy       Date:  1999-03       Impact factor: 5.018

2.  Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants.

Authors:  E S Silverman; J Du; G T De Sanctis; O Rådmark; B Samuelsson; J M Drazen; T Collins
Journal:  Am J Respir Cell Mol Biol       Date:  1998-08       Impact factor: 6.914

3.  Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity.

Authors:  A Sampson; S Holgate
Journal:  BMJ       Date:  1998-04-25

4.  Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.

Authors:  M Sanak; H U Simon; A Szczeklik
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

5.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

6.  The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma.

Authors:  Z Diamant; J T Hiltermann; E L van Rensen; P M Callenbach; M Veselic-Charvat; H van der Veen; J K Sont; P J Sterk
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

7.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

8.  Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.

Authors:  H M Sarau; R S Ames; J Chambers; C Ellis; N Elshourbagy; J J Foley; D B Schmidt; R M Muccitelli; O Jenkins; P R Murdock; N C Herrity; W Halsey; G Sathe; A I Muir; P Nuthulaganti; G M Dytko; P T Buckley; S Wilson; D J Bergsma; D W Hay
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

9.  Leukotriene E4 and granulocytic infiltration into asthmatic airways.

Authors:  L A Laitinen; A Laitinen; T Haahtela; V Vilkka; B W Spur; T H Lee
Journal:  Lancet       Date:  1993-04-17       Impact factor: 79.321

10.  Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.

Authors:  J A Leff; W W Busse; D Pearlman; E A Bronsky; J Kemp; L Hendeles; R Dockhorn; S Kundu; J Zhang; B C Seidenberg; T F Reiss
Journal:  N Engl J Med       Date:  1998-07-16       Impact factor: 91.245
View more
  43 in total

Review 1.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 2.  Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.

Authors:  Roberta Russo; Mario Capasso; Paolo Paolucci; Achille Iolascon
Journal:  Eur J Clin Pharmacol       Date:  2010-11-11       Impact factor: 2.953

3.  Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.

Authors:  John J Lima; Shu Zhang; Audrey Grant; Lianhe Shao; Kelan G Tantisira; Hooman Allayee; Jianwei Wang; James Sylvester; Janet Holbrook; Robert Wise; Scott T Weiss; Kathleen Barnes
Journal:  Am J Respir Crit Care Med       Date:  2005-11-17       Impact factor: 21.405

Review 4.  Asthma Pharmacogenomics: 2015 Update.

Authors:  Joshua S Davis; Scott T Weiss; Kelan G Tantisira
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

Review 5.  Pharmacogenetics of asthma.

Authors:  John J Lima; Kathryn V Blake; Kelan G Tantisira; Scott T Weiss
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

Review 6.  Aspirin-induced asthma: clinical aspects, pathogenesis and management.

Authors:  Ahmed M Hamad; Amy M Sutcliffe; Alan J Knox
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Pharmacogenetics of asthma in children.

Authors:  Naomi Kondo; Eiko Matsui; Akane Nishimura; Hideo Kaneko
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

9.  Role of genetic polymorphisms in therapeutic response to anti-asthma therapy.

Authors:  John Oppenheimer
Journal:  Allergy Asthma Clin Immunol       Date:  2007-06-15       Impact factor: 3.406

10.  Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma.

Authors:  I Sayers; S Barton; S Rorke; B Beghé; B Hayward; P Van Eerdewegh; T Keith; J B Clough; S Ye; J W Holloway; A P Sampson; S T Holgate
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.